{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.47","upperLimit":"14.43","value":"11.23"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"143"}],"units":"Participants"}],"description":"OS was defined as the time from allocation to death due to any cause. To report the median survival (in months) and the associated 95%CIs were reported using Kaplan-Meier method was used. Participants without documented death at the time of final analysis were censored at the date of the last follow up.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants receive vorinostat 400 mg, orally, once daily (QD) on Days 1-14 of each 21-day treatment cycle and bortezomib 1.3mg/m\\^2 intravenous (IV) injection QD on Days 1, 4, 8 and 11 of each 21-day treatment cycle for up to 26 cycles. Participants with progressive disease (PD) after 2 cycles of treatment or no change (NC) after 4 cycles of treatment receive additional treatment of Dexamethasone, 20 mg of total daily dose, orally on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21-day treatment cycle for up to 26 cycles. Eligible participants could receive additional treatment on an extension.","id":"OG000","title":"Vorinostat + Bortezomib"}],"paramType":"MEDIAN","populationDescription":"All allocated participants","reportingStatus":"POSTED","timeFrame":"Up to approximately 40 months (through End of Trial data cut-off of 09-Apr-2012)","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}